menu
    • menu

    Company profile for ImmunoMet

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria and decreases the energy supply of resistant cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with good tolerability and ImmunoMet anticipates initiating Phase 2 PoC ...
    ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria and decreases the energy supply of resistant cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with good tolerability and ImmunoMet anticipates initiating Phase 2 PoC studies in oncology next year.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunoMetUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    JLABS@TMC 2450 Holcombe Blvd, Houston, TX 77021
    Telephone
    Telephone
    (+1) 346-772-0318
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immunomet.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunoMet's Phase 1b Lixumistat Pancreatic Cancer Data At ASCO GI
    ImmunoMet's Phase 1b Lixumistat Pancreatic Cancer Data At ASCO GI

    24 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250124250527/en

    BUSINESSWIRE
    24 Jan 2025
    Share Share
    NIMML Institute Presents LANCL Receptor Research at Immunology2024
    NIMML Institute Presents LANCL Receptor Research at Immunology2024

    10 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240410022187/en

    BUSINESSWIRE
    10 Apr 2024
    Share Share
    ImmunoMet Therapeutics Announces First Patient Dosed in a Ph 1b Trial of IM156
    ImmunoMet Therapeutics Announces First Patient Dosed in a Ph 1b Trial of IM156

    17 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221117005817/en

    BUSINESSWIRE
    17 Nov 2022
    Share Share
    Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
    Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer

    26 Jul 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210726005804/en

    BUSINESSWIRE
    26 Jul 2021
    Share Share
    ImmunoMet Therapeutics Granted Fast Track Designation by USFDA for IM156
    ImmunoMet Therapeutics Granted Fast Track Designation by USFDA for IM156

    03 May 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210503005641/en

    BUSINESSWIRE
    03 May 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search